Quarterly ResultMay 6, 2026, 08:13 AM
InflaRx Q1 Loss Narrows to 5.6M; Restructures, Focuses on Izicopan
AI Summary
InflaRx N.V. reported a net loss of 5.6 million for Q1 2026, a significant improvement from the 8.3 million loss in Q1 2025. This reduction was driven by a strategic restructuring announced in January 2026, which included a workforce reduction and discontinuation of GOHIBIC (vilobelimab) sales activities in the US. The company is now focusing its resources predominantly on the clinical development of izicopan. Dr. Camilla Chong will also resign as Chief Medical Officer in August 2026.
Key Highlights
- Net loss for Q1 2026 was 5.6 million, down from 8.3 million in Q1 2025.
- Operating loss improved to 7.2 million in Q1 2026 from 13.0 million in Q1 2025.
- Sales and marketing expenses decreased to 0.1 million in Q1 2026 from 1.5 million in Q1 2025.
- Research and development expenses fell to 4.2 million in Q1 2026 from 7.0 million in Q1 2025.
- General and administrative expenses decreased to 3.2 million in Q1 2026 from 5.1 million in Q1 2025.
- Cash and cash equivalents stood at 15.0 million as of March 31, 2026, down from 16.0 million at year-end 2025.
- Incurred 0.6 million in additional one-time restructuring costs in Q1 2026.
- Dr. Camilla Chong will resign as Chief Medical Officer, effective August 2026.